Autobahn Acquires Global Rights to Astellas' ASP3652 to Bolster its Brain Targeting Chemistry Platform
Shots:
- Autobahn acquires global IP- development- and regulatory rights to ASP3652 to strengthen its brain-targeting chemistry platform. The addition of ASP3652 will accelerate the delivery of next-generation brain-targeting prodrugs for CNS disorders- particularly MS
- ASP3652 complements Autobahn’s brain-targeting chemistry platform- which uses FAAH-mediated prodrug conversion to enable the delivery of small molecules across the BBB. The company may develop ASP3652 in combination with multiple pipeline programs- including Autobahn’s TRβ agonists for MS
- ASP3652 is a FAAH inhibitor- previously been evaluated across 10 clinical studies in ~200 patients
Ref: BUSINESS WIRE | Image: BioSpace
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com